.svg)
.webp)
.webp)
.webp)
.svg){kind=icon}
Qsymia® is a prescription medication FDA-approved for chronic weight management in adults and pediatric patients aged 12 years and older with obesity, or in adults with overweight who have at least one weight-related health condition, like high blood pressure, type 2 diabetes, or high cholesterol.
It combines two well-studied medications, phentermine and topiramate extended-release, each of which works through a different pathway to help reduce appetite and support weight management. Together, the combination has been shown to produce greater weight reduction than either component alone.
Unlike injectable GLP-1 medications, Qsymia® is taken as a once-daily oral capsule, making it a convenient option for people who prefer not to use injections.
Qsymia® is available in multiple dose strengths and is started at a low dose, then gradually increased. Your care team will help determine whether it's the right fit based on your health history, goals, and treatment needs.
.svg)
Qsymia® works through two active ingredients that each target appetite through a different pathway.
Phentermine acts on the central nervous system to reduce appetite. It triggers the release of a chemical messenger in the brain that activates the body's natural appetite-suppressing signals, reducing the drive to eat.
Topiramate extended-release is a medication traditionally used to treat epilepsy and migraines, but it was also found to reduce appetite and support weight reduction. Exactly how it does this isn't fully understood, but it's thought to work through several brain pathways that influence feelings of fullness and the desire to eat.
By working through two distinct pathways simultaneously, Qsymia® helps reduce hunger, increase feelings of fullness, and lower overall caloric intake, making it easier to maintain dietary changes as part of a broader care plan.
The extended-release formulation of topiramate is specifically designed to deliver a steady, gradual level of the medication throughout the day, supporting consistent appetite control.
Qsymia® can be covered by insurance, but it depends on your plan.
Insurance coverage for Qsymia® varies by plan, employer, and whether weight management medications are included in your benefits. Coverage is typically most common when prescribed for obesity or overweight with a related health condition, which are FDA-approved indications for the medication.
Prior authorization may be required. Plans may ask for documentation of a qualifying diagnosis, BMI, and any previous medications tried.
knownwell helps patients navigate this process. Our dedicated authorization team can assist with prior benefit verification and next steps, so you understand your coverage options before moving forward.
.svg)
.svg%201%20%5BVectorized%5D%20(1).svg)
With commercial insurance coverage, Qsymia® can cost as little as $2.33 per day ($70 per month) using the Qsymia® Savings Card. Actual costs vary based on your plan, benefits, pharmacy, and prescribed dose.
knownwell's care team helps review your coverage and navigate any required approvals, so you understand your options before starting treatment.
For patients paying without insurance, Qsymia® is available through the Qsymia® home delivery pharmacy at:
Your knownwell care team can help you explore your options and review costs with you as part of your plan.
It is also available generically for $60/mo with GoodRx coupon.
.svg)
.svg){kind=icon}
Commercially insured patients may pay as little as $60 per month with the Qsymia® Savings Card. Terms and conditions apply.
Prescribed as part of a personalized medication plan with ongoing support from your knownwell care team.
Clinical studies show that Qsymia® can support meaningful, sustained weight reduction for many people when used consistently as part of a broader care plan that includes a reduced-calorie diet and increased physical activity.
The CONQUER study, a 56-week phase 3 clinical trial of nearly 2,500 adults with overweight or obesity and at least two weight-related health conditions, showed participants lost an average of 7.8% of their body weight on the recommended dose (7.5 mg / 46 mg) and 9.8% on the top dose (15 mg / 92 mg), compared to 1.2% with placebo.
%202.svg)
The EQUIP study, a 56-week phase 3 trial of nearly 1,300 adults with overweight, showed participants taking the top dose (15 mg / 92 mg) lost an average of 10.9% of their body weight, and 47% of participants achieved 10% or more weight reduction, compared to 7% with placebo.
The SEQUEL study, a 108-week extension of the CONQUER trial, showed Qsymia® demonstrated significant, sustained weight reduction through two years of treatment, along with improvements in cardiometabolic markers, including blood sugar, cholesterol, and blood pressure.
.png)
%202%20(1).svg)
Common Qsymia® side effects in adults include tingling or numbness in the hands or feet (paraesthesia), dizziness, changes in taste (dysgeusia), trouble sleeping, constipation, and dry mouth, especially when starting or increasing the dose.
These things typically improve as your body adjusts.
Qsymia® is not appropriate for people who are pregnant or planning to become pregnant, have glaucoma, have an overactive thyroid (hyperthyroidism), are taking monoamine oxidase inhibitors (MAOIs), or have a known allergy or sensitivity to phentermine, topiramate, or any inactive ingredient in Qsymia®.
People who can become pregnant must use effective birth control while taking Qsymia® due to the risk of birth defects. Qsymia® is available only through certified pharmacies as part of a Risk Evaluation and Mitigation Strategy (REMS) program.
Your knownwell care team will review your full health history to determine whether Qsymia® is a safe option for you.
Qsymia® is taken as a once-daily oral capsule, in the morning, with or without food. It shouldn’t be taken in the evening, as it may cause difficulty sleeping.
Qsymia® should be stored at room temperature, away from heat and moisture. Your knownwell care team will review proper storage and handling instructions for your prescription.
Qsymia® is started at the lowest available dose (3.75 mg / 23 mg) for the first two weeks, then increased to the recommended dose (7.5 mg / 46 mg). If additional weight management is needed after 12 weeks, the dose may be increased to 11.25 mg / 69 mg for two weeks before reaching the maximum dose (15 mg / 92 mg).
The highest dose (15 mg / 92 mg) must be tapered gradually before stopping. It shouldn’t be discontinued abruptly, as this may increase the risk of seizure.
Your knownwell care team will review your specific dosing plan and make adjustments based on how your body responds.
Yes, Qsymia® does require special monitoring. Before starting and during treatment, your provider will recommend blood tests to check kidney function, electrolyte levels, and blood sugar (if you have diabetes).
People who can become pregnant will need a monthly pregnancy test while taking Qsymia®.
For adolescent patients, your provider will also monitor height and bone development during treatment, as Qsymia® may affect bone mineral density and growth rate in younger patients.
%20(1).png)
.png)
%20(1)%201.png)
Meet with a knownwell provider to review your options, discuss whether Qsymia® fits your needs, and get guidance on next steps.
knownwell knows that long-term weight management support is critical. That's why our patients meet with the same clinician throughout their entire time at knownwell.
A closer look at GLP-1 receptor biology, peptide engineering, and metabolic effects
Qsymia® is a carefully engineered combination of two FDA-approved medications: phentermine and topiramate extended-release.
Each ingredient works through a different biological pathway. Together, they produce greater weight reduction than either medication alone, at doses lower than those used when either drug is prescribed by itself.
Phentermine is a sympathomimetic amine anorectic: a class of compounds that stimulate the central nervous system. It promotes the release of norepinephrine in the brain, which activates appetite-suppressing pathways and reduces the drive to eat. The result is reduced appetite and decreased food intake.
Topiramate extended-release was originally developed to treat epilepsy and migraines. Its weight-reducing effects were observed in clinical use and have since been studied extensively.
The precise mechanism behind its weight-management effects is unknown but thought to involve multiple pathways: augmentation of GABA activity, modulation of voltage-gated ion channels, inhibition of AMPA/kainate glutamate receptors, and carbonic anhydrase inhibition, all of which may influence food reward, satiety signaling, and caloric intake.
The extended-release formulation of topiramate is specifically designed to deliver the medication gradually and steadily, helping to minimize side effects associated with higher peak concentrations.
Both phentermine and topiramate act primarily in the central nervous system, targeting the brain pathways responsible for appetite, hunger, and reward-driven eating.
Phentermine stimulates the release of norepinephrine, activating appetite-suppressing pathways. It reduces the desire to eat and reduces overall food intake.
Topiramate is thought to act across multiple brain pathways involved in appetite and satiety. There, it modulates neurotransmitter activity to reduce food reward signaling and supports longer-lasting feelings of fullness.
Together, these complementary central mechanisms create a more comprehensive effect on appetite than either ingredient alone.
In clinical trials, Qsymia® has been associated with improvements in cardiometabolic markers beyond weight management alone, including:
The SEQUEL study (a 108-week extension of the CONQUER trial) showed maintained cardiometabolic improvements alongside sustained weight reduction over two years of treatment.
Important note about pregnancy: Because of the risk of birth defects, Qsymia® is only available through certified pharmacies under a REMS program. People who can become pregnant must have a negative pregnancy test before starting Qsymia® and monthly during treatment, and must use effective birth control while taking it.
Talk with your provider if you have a history of:
Some side effects require prompt medical attention, including:
Your knownwell care team will review your health history, medications, and safety considerations before prescribing Qsymia® and will continue to support you throughout treatment.
.png)
.png)
.webp)
Get started with weight management care at knownwell.
